CoChat

The Oral Insulin Sensitizer, Thiazolidinedione, Increases Plasma Vascular Endothelial Growth Factor in Type 2 Diabetic Patients

Open access
Baba, Tsuneharu, Shimada, Koichi, Neugebauer, Sabine, Yamada, Daishiro, Hashimoto, Shigeatsu, Watanabe, Tsuyoshi · 2001 · Diabetes Care
Cited by 58

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In the Presidential Address in June of 1998 (1), I proudly announced that the recently adopted Five Year Plan of the American Diabetes Association (ADA) contained the goal of allocating one of every three dollars of total public support to research awards and grants by the end of five years.I pledged to keep the members of the Professional Section apprised of our progress toward that goal.The general approach envisaged gradual increases in funding during the first three years, with more steep increases during the final two years.During the baseline fiscal year (FY) of 1998, before the initiation of the Five Year Plan, total public support was 90.8 million dollars, of which 15.5 million dollars, or 17.1%, was devoted to research awards and grants.During FY 1999, the first year of the Five Year Plan, total public support was 101.6 million dollars, of which 18.2 million dollars, or 17.9%, went to research awards and grants.During the past year, FY 2000, the second year of the Five Year Plan, total public support was 117.8 million dollars, of which 22.4 million dollars, or 19.0%, was allocated to research awards and grants.Although the largest increases are due in the final two years, we still have a long way to go.Members of the Professional Section need to use their influence (with both their patients and the ADA) to ensure that this ambitious goal is reached.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.24.5.953

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 58

Metadata

Authors
Baba, T., Shimada, K., Neugebauer, S., Yamada, D., Hashimoto, S., & Watanabe, T.
Venue
Diabetes Care
Published
2001-05-01
Volume
24
Issue
5
Pages
953-954
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2168294324
Cited by
58
References
2
FWCI
3.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Oral Insulin Sensitizer, Thiazolidinedione, Increases Plasma Vascular Endothelial Growth Factor in Type 2 Diabetic Patients. https://app.cochat.ai/papers/10.2337/diacare.24.5.953
The paper
Baba, T., Shimada, K., Neugebauer, S., Yamada, D., Hashimoto, S., & Watanabe, T. (2001). The Oral Insulin Sensitizer, Thiazolidinedione, Increases Plasma Vascular Endothelial Growth Factor in Type 2 Diabetic Patients. Diabetes Care. https://doi.org/10.2337/diacare.24.5.953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.